Diferencia entre revisiones de «Tirzepatide»
Sin resumen de edición |
Sin resumen de edición |
||
| Línea 1: | Línea 1: | ||
Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment | Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment | ||
==Side Effects== | |||
*Pancreatitis | |||
*Nausea | |||
*Vomiting | |||
*Abdominal pain | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revisión actual - 05:25 20 ago 2022
Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment
Side Effects
- Pancreatitis
- Nausea
- Vomiting
- Abdominal pain